These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 27492661)

  • 21. [Predictive value of the early metabolic response in patients with advanced-stage non-small cell lung cancer].
    Moreno C; Mourelo S; Soler M; Moragas M; Riera E; Garcia JR
    Rev Esp Med Nucl Imagen Mol; 2014; 33(5):324-5. PubMed ID: 24418117
    [No Abstract]   [Full Text] [Related]  

  • 22. Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.
    López-Ayllón BD; de Castro-Carpeño J; Rodriguez C; Pernía O; Ibañez de Cáceres I; Belda-Iniesta C; Perona R; Sastre L
    Int J Clin Exp Pathol; 2015; 8(3):2888-98. PubMed ID: 26045797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes.
    Fraser A
    N Z Med J; 2017 Mar; 130(1451):11-20. PubMed ID: 28253240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma.
    Zhuang H; Bai J; Chang JY; Yuan Z; Wang P
    Oncotarget; 2016 Dec; 7(51):84688-84694. PubMed ID: 27713162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.
    Monnet I; Audigier-Valette C; Girard N; Vergnenègre A; Molinier O; Souquet PJ; Blanchon F; Bonnetain F; Taguieva-Pioger N; Lamour C; Wislez M
    Lung Cancer; 2016 Aug; 98():84-90. PubMed ID: 27393512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resolution of vocal fold leukoplakia during erlotinib treatment for lung cancer.
    Francis DO; Misono S; Somerville J; McWhorter A; Garrett CG
    Ear Nose Throat J; 2016 Feb; 95(2):65-7. PubMed ID: 26930330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
    Chanprapaph K; Pongcharoen P; Vachiramon V
    Indian J Dermatol Venereol Leprol; 2015; 81(5):547. PubMed ID: 25994883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generic oncology drugs: are they all safe?
    Yang YT; Nagai S; Chen BK; Qureshi ZP; Lebby AA; Kessler S; Georgantopoulos P; Raisch DW; Sartor O; Hermanson T; Kane RC; Hrushesky WJ; Riente JJ; Norris LB; Bobolts LR; Armitage JO; Bennett CL
    Lancet Oncol; 2016 Nov; 17(11):e493-e501. PubMed ID: 27819247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
    Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
    Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
    Spigel DR; Edelman MJ; O'Byrne K; Paz-Ares L; Mocci S; Phan S; Shames DS; Smith D; Yu W; Paton VE; Mok T
    J Clin Oncol; 2017 Feb; 35(4):412-420. PubMed ID: 27937096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
    Kelly K; Altorki NK; Eberhardt WE; O'Brien ME; Spigel DR; Crinò L; Tsai CM; Kim JH; Cho EK; Hoffman PC; Orlov SV; Serwatowski P; Wang J; Foley MA; Horan JD; Shepherd FA
    J Clin Oncol; 2015 Dec; 33(34):4007-14. PubMed ID: 26324372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Generics and brands in chemotherapy].
    Grigor'ev VIu
    Antibiot Khimioter; 2006; 51(8):38-47. PubMed ID: 18030783
    [No Abstract]   [Full Text] [Related]  

  • 35. Experience with erlotinib in the treatment of non-small cell lung cancer.
    Landi L; Cappuzzo F
    Ther Adv Respir Dis; 2015 Aug; 9(4):146-63. PubMed ID: 26063687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
    Klughammer B; Brugger W; Cappuzzo F; Ciuleanu T; Mok T; Reck M; Tan EH; Delmar P; Klingelschmitt G; Yin AY; Spleiss O; Wu L; Shames DS
    J Thorac Oncol; 2016 Apr; 11(4):545-55. PubMed ID: 26773740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer.
    Cho SL; Lin WC; Chuang CA; Liao WY; Lai CF
    Nephrology (Carlton); 2020 Sep; 25(9):730. PubMed ID: 32364270
    [No Abstract]   [Full Text] [Related]  

  • 38. Corneal edema with a systemic epidermal growth factor receptor inhibitor.
    Höllhumer R; Moloney G; Jacob K
    Can J Ophthalmol; 2017 Jun; 52(3):e96-e97. PubMed ID: 28576229
    [No Abstract]   [Full Text] [Related]  

  • 39. Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.
    Takeda M; Okamoto I; Fukuoka M; Nakagawa K
    J Clin Oncol; 2010 Jun; 28(17):e273-4. PubMed ID: 20385983
    [No Abstract]   [Full Text] [Related]  

  • 40. A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.
    Suleiman AA; Frechen S; Scheffler M; Zander T; Nogova L; Kocher M; Jaehde U; Wolf J; Fuhr U
    AAPS J; 2015 Nov; 17(6):1483-91. PubMed ID: 26286677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.